



Research Article

From Hepatic Enzyme Alterations to Drug Metabolic Dysfunction: A Systematic Review of Prolonged Pharmacotherapy

Sarthak Satapathy^{1*}, Shalu Singh² and Ravi Ranjan Singh³

¹Assistant Professor, Department of Community Medicine, Pabitra Mohan Pradhan Medical College and Hospital, Talcher, Odisha, India

²Senior Tutor, Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad, Uttar Pradesh, India

³Associate Professor, Department of Pathology, Autonomous State Medical College, Kaushambi, Manjhanpur, Uttar Pradesh, India

***Corresponding Author**

Sarthak Satapathy
(drsarthaksatapathy17@gmail.com)

Article History

Received: 12.09.2026

Accepted: 25.09.2026

Published: 18.10.2026

doi: 10.61336/jdme.0704.10

Abstract: **Background:** Prolonged exposure to medicines may produce laboratory abnormalities, clinically significant hepatic injury, or changes in hepatic drug-metabolizing enzyme activity. These phenomena overlap but are not interchangeable. **Objective:** To critically synthesize human evidence connecting repeated or extended pharmacotherapy with hepatic enzyme alterations, liver injury and altered drug disposition. **Methods:** A structured search of PubMed/MEDLINE-indexed records, accessible full-text articles and publisher databases identified clinical trials, longitudinal cohorts, comparative studies, pharmacokinetic experiments and a chronic-exposure histopathological case series. The PRISMA selection accounting presents 811 records identified, 164 duplicates removed, 647 records screened, 120 full-text reports assessed and 14 primary reports included in the domain-based narrative synthesis. Findings were organized into biochemical injury, clinically significant hepatotoxicity, enzyme induction, enzyme inhibition and cumulative structural damage; reported effect estimates and denominators were preserved. **Results:** In a randomized trial of 4,786 adults, liver-test elevations occurred in 43.6% with low-dose methotrexate versus 24.1% with placebo (hazard ratio 2.14, 95% confidence interval 1.93-2.37). In a 213-person methotrexate cohort, 21% developed alanine aminotransferase >1.5 times the upper limit of normal over a mean 4.3 years. A study of 1,928 tuberculosis-treatment recipients recorded drug-induced liver injury in 3.0%, whereas a randomized latent-tuberculosis trial found grade 3-4 hepatitis in 16/422 isoniazid versus 3/418 rifampin recipients. Conversely, in 232,889 propensity-matched statin initiators in each baseline ALT stratum, severe acute liver injury was uncommon, with a pooled hazard ratio of 1.15 (95% confidence interval 0.75-1.75) comparing elevated versus normal baseline ALT. CYP3A functional studies found oral midazolam exposure only 5.7% of control values in patients taking carbamazepine or phenytoin, but 12.4-fold greater after 14 days of ritonavir-boosted saquinavir. **Conclusion:** Hepatic biochemical abnormalities neither universally indicate hepatocellular dysfunction nor predict a uniform change in drug clearance. Extended treatment can cause hepatotoxicity, produce adaptive enzyme induction or inhibition, or, less commonly, lead to structural hepatic disease. Drug-specific longitudinal monitoring and pharmacokinetic assessment are complementary.

Keywords: Drug-Induced Liver Injury, Prolonged Pharmacotherapy, Aminotransferases, Gamma-Glutamyltransferase, Cytochrome P450, Hepatic Clearance, Methotrexate, Statins, Antituberculosis Treatment, Enzyme Induction, Drug-Drug Interactions

Copyright @ 2026: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

The liver is a central organ of xenobiotic biotransformation, integrating phase I oxidation, phase II conjugation, transporter-mediated uptake and efflux, bile formation and systemic clearance. Long-term prescribing therefore poses two distinct hepatic questions: whether a medication injures the liver and whether continued drug exposure changes the handling of that medicine or coadministered therapies. These questions are often conflated when an abnormal Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), or Gamma-Glutamyltransferase (GGT) is interpreted as evidence of altered drug metabolism.

ALT and AST are predominantly indicators of hepatocyte injury rather than direct measures of enzymatic drug clearance. ALP and GGT help characterize cholestatic or enzyme-induction patterns but are not specific tests of metabolic capacity. Bilirubin, International Normalized Ratio (INR) and albumin can contribute evidence of excretory or synthetic dysfunction, although each has clinical limitations. The AASLD practice guidance emphasizes compatible drug exposure, temporal chronology, exclusion of competing causes and biochemical phenotype in evaluating suspected Drug-Induced Liver Injury (DILI) [1,2].

The range of long-term medication effects is pharmacologically heterogeneous. Weekly methotrexate may be accompanied by recurrent ALT elevations and, in selected patients, chronic injury; antituberculosis regimens may cause clinically meaningful hepatitis within a planned months-long course; enzyme-inducing antiepileptics may substantially

increase CYP-mediated elimination of coadministered substrates; protease inhibitors may inhibit CYP3A and substantially increase substrate exposure. Statins, by contrast, can be prescribed safely in many patients with stable chronic liver disease, underscoring why elevated baseline ALT alone is not a reliable indicator of clinically severe toxicity [3-15].

Rationale and Review Objectives

Existing clinical literature frequently examines hepatotoxicity separately from pharmacokinetic drug-drug interactions. Integrating these domains is valuable because biochemical injury, hepatic enzyme induction and depressed drug clearance have different biological substrates, clinical implications and monitoring requirements. The central objective was to evaluate how repeated or long-duration pharmacotherapy affects (1) serial liver biochemistry; (2) clinically significant hepatic injury; (3) functional CYP-mediated drug metabolism; (4) exposure-related structural hepatic changes; and (5) the degree to which routine liver tests predict metabolic dysfunction.

MATERIALS AND METHODS

Review Design and Reporting Framework

The review used a structured, domain-based synthesis of primary human evidence and was organized using PRISMA 2020 reporting concepts [1]. The research question was framed using population, exposure, comparator, outcome and study-design elements. The population consisted of adults receiving repeated-dose prescription pharmacotherapy or healthy volunteers exposed to repeated dosing for pharmacokinetic phenotyping. Exposures included methotrexate, statins, antituberculosis drugs, phenytoin, carbamazepine, antiretroviral protease inhibitor regimens and amiodarone. Comparators included placebo, alternative agents, untreated controls, baseline status, or between-regimen exposure levels. The outcomes were liver-test changes, hepatitis, clinically severe liver injury, histopathological evidence and quantified pharmacokinetic parameters.

Information Sources and Search Strategy

Targeted searches were conducted on 19 June 2026 using PubMed/MEDLINE-indexed source pages, PubMed Central accessible full texts and primary publisher records. Searches combined medication names with the concepts "long term," "prolonged," "hepatotoxicity," "ALT," "AST," "GGT," "alkaline phosphatase," "drug-induced liver injury," "CYP3A4," "midazolam," "enzyme induction," "enzyme inhibition," "pharmacokinetics," and "liver metabolism." Additional searches traced the cited primary clinical studies from relevant therapeutic and DILI guidance articles. Numerical findings were checked against primary abstracts or full-text tables whenever available.

Eligibility and Exposure-Duration Framework

Eligible primary clinical evidence comprised randomized controlled trials, prospective or retrospective observational studies, comparative studies and *in-vivo* pharmacokinetic studies with quantified measures. To represent extended therapeutic exposure, clinical safety studies evaluated prescribed courses intended to continue for at least four weeks or established chronic treatment. For mechanistic phenotyping, repeated-dose induction or inhibition studies of at least 14 days were eligible, as this interval permits time-dependent changes in enzyme activity to be measured under multiple-dose conditions. Histological reports were restricted to sustained medication exposure; a small amiodarone biopsy series was retained specifically for structural mechanistic evidence, rather than for incidence estimation. Single-dose interaction reports, purely animal experiments, modeling-only reports, nonextractable case narratives and secondary reviews were not treated as primary outcome studies.

Outcome Definitions and Synthesis

Serum aminotransferase changes were retained using each original study's threshold. Events called "hepatitis" or DILI were retained according to the source definition, rather than retrospectively assigned a uniform threshold. Clinically significant DILI was distinguished from lower-grade biochemical abnormalities using published guidance [2]. Drug disposition was quantified using parent-drug area under the plasma concentration-time curve (AUC), maximum concentration (C_{max}), elimination half-life, or substrate/metabolite ratio. A pooled meta-analysis was not conducted because populations, durations, liver-test thresholds, drug classes, causal mechanisms and experimental designs were substantially heterogeneous. Findings are presented by domain, with denominators and intervals whenever published.

Study-Level Methodological Appraisal and Evidence Certainty

Study limitations were examined across selection, exposure ascertainment, comparator adequacy, confounding, endpoint validity, temporal follow-up and generalizability. Randomization and blinding were emphasized for comparative treatment safety; baseline comparability, assay validity and repeated measures were emphasized for pharmacokinetic studies. Interpretation of certainty considered consistency, directness, effect magnitude, precision and residual confounding rather than combining fundamentally dissimilar endpoints into a single summary estimate.

RESULTS

Study Selection and PRISMA 2020 Accounting

Figure 1 presents the numerical study-selection pathway. The identification stage contains 782 records from database-indexed sources and 29 from reference searches or other methods (811 total). After removal of 164 duplicates, 647 unique records proceeded to title-and-abstract screening; 521 were excluded. Of 126 reports sought, six could not be retrieved, leaving 120 full-text reports assessed for eligibility. A further 106 full-text reports were excluded: ineligible study design (n = 33), unrelated hepatic or pharmacokinetic outcome (n = 29), insufficient exposure duration (n = 22), insufficient extractable data (n = 13) and overlapping participant populations (n = 9). The resulting qualitative synthesis comprised 14 primary reports.

Characteristics of the Evidence Base

Fourteen primary investigations informed the synthesis: randomized trials and post-randomization safety analyses, population and longitudinal cohorts, comparative anticonvulsant studies, repeated-dose CYP3A probe studies and a biopsy-confirmed chronic amiodarone series. Exposure duration ranged from 14 days in controlled metabolic phenotyping to several years in clinical safety and histopathological investigations. Table 1 distinguishes the outcome domains and Table 2 summarizes the primary investigations and numerical findings.

Hepatic Enzyme Abnormalities during Long-Term Methotrexate Exposure

The clearest randomized evidence for repeated therapy-associated liver-test elevation was provided by Solomon *et al.* [3]. Among 2,391 individuals allocated to low-dose methotrexate and 2,395 to placebo, 1,042 (43.6%) and 576 (24.1%), respectively, experienced study-defined liver-test elevations. The hazard ratio was 2.14 (95% CI 1.93-2.37). Moderate elevations were reported in 187 (7.8%) and 49 (2.1%), respectively (HR 3.94, 95% CI 2.87-5.39), while severe elevations were reported in 69 (2.9%) and 26 (1.1%) (HR 2.67, 95% CI 1.70-4.19). The trial’s run-in excluded participants unable to tolerate methotrexate prior to randomization; despite this selection, a measurable elevation signal remained. These outcomes were biochemical safety endpoints and should not be equated with histologically established liver fibrosis or loss of drug-clearance function.

In clinical rheumatoid arthritis practice, Karlsson *et al.* [4] followed 213 methotrexate starters for a mean 4.3 years and reviewed 6,288 ALT tests. ALT exceeded the ULN in 84 patients (39%), exceeded 1.5× ULN in 44 (21%), exceeded 2× ULN in 32 (15%) and exceeded 3× ULN in 13 (6%); seven (3%) stopped methotrexate permanently because of ALT elevation. Pretreatment ALT abnormality was associated with later >1.5× ULN elevation (adjusted odds ratio 6.8; 95% CI 2.2-20.5). The contrast between the trial and cohort demonstrates how study populations, laboratory definitions, monitoring density and pretreatment vulnerability shape observed event rates; direct numerical pooling would be misleading.




Figure 1: PRISMA 2020 Flow Diagram of Evidence Identification, Screening, Eligibility and Inclusion

Table 1: Domains and Interpretation of Measures

Domain	Principal measures	Interpretation
Biochemical response	ALT, AST, ALP, GGT above study-defined limits	May indicate injury, cholestasis or enzyme induction; does not alone quantify drug clearance
Clinically significant hepatic injury	Defined DILI, grade 3-4 hepatitis, bilirubin/INR outcomes	Supports clinical injury assessment, with cause attribution required
Metabolic induction	Decreased substrate AUC/Cmax, altered half-life	Indicates faster apparent removal or reduced bioavailability; intestinal and hepatic effects may coexist
Metabolic inhibition	Increased substrate AUC/Cmax, prolonged half-life	Indicates reduced apparent drug metabolism or altered transport/bioavailability
Structural/cumulative effects	Biopsy fibrosis, cirrhosis, phospholipidosis	Demonstrates tissue injury but does not automatically quantify CYP activity

Table 2: Characteristics and Numerical Findings of Included Primary Reports

Study	Design and exposure	Population/duration	Principal findings
Solomon <i>et al.</i> [3]	Double-blind randomized trial; methotrexate Vs placebo	4,786 randomized; median 23 months	Liver-test elevations 1,042/2,391 (43.6%) Vs 576/2,395 (24.1%); HR 2.14 (95% CI 1.93-2.37).
Karlsson <i>et al.</i> [4]	Longitudinal rheumatoid arthritis cohort; methotrexate	213; mean treatment 4.3 years; 6,288 ALT tests	44/213 (21%) ALT >1.5× ULN; 13/213 (6%) >3× ULN; 7 (3%) discontinued permanently.
Lewis <i>et al.</i> [5]	Double-blind RCT; pravastatin 80 mg Vs placebo in compensated liver disease	326 randomized; 36 weeks safety	Primary prespecified ALT events numerically lower on pravastatin, nonsignificant; baseline NAFLD 64%, HCV 23%
Athyros <i>et al.</i> [6]	GREACE post-hoc comparison; statins in abnormal baseline liver tests	437 subgroup; approximately 3 years	Cardiovascular events 22/227 (10%) statin Vs 63/210 (30%) no statin; liver tests improved in treated group
Verma <i>et al.</i> [7]	Propensity-matched claims-based statin initiation cohorts	232,889 matched in each ALT category	Severe acute liver injury ~19/100,000 person-years; HR 1.15 (95% CI 0.75-1.75), high Vs normal ALT
Menzies <i>et al.</i> [8]	Multicentre open-label RCT; four months rifampin Vs nine months isoniazid	840 started regimens: 418 rifampin, 422 isoniazid	Grade 3-4 hepatitis 3/418 vs 16/422; completion 78% Vs 60%
Menzies <i>et al.</i> [9]	Multicountry adult RCT; four months rifampin Vs nine months isoniazid	>6,800 adults; months-long regimens	Within 146 days, grade 3-5 hepatotoxic event difference -1.2 percentage points (95% CI -1.7 to -0.7), favoring rifampin
Tweed <i>et al.</i> [10]	REMOxTB clinical-trial cohort analysis; months-long TB regimens	1,928; enzyme testing to week 17	DILI 58/1,928 (3.0%); median onset 28 days (IQR 14-56)
Keeffe <i>et al.</i> [11]	Before-after chronic phenytoin biochemical study	58; 6 months, follow-up to 24 months	GGT increased in 52/58 (90%); mean 45.2 to 135.8 U/L at six months
Aldenhövel [12]	Retrospective phenytoin Vs carbamazepine monotherapy comparison	110; long-term therapy	Elevated GGT: 91% Vs 64%; elevated ALP: 39% Vs 14%
Backman <i>et al.</i> [13]	Comparative clinical CYP3A phenotyping in treated epilepsy	6 treated patients and 7 controls	Midazolam AUC 5.7% and Cmax 7.4% of controls; half-life 1.3 Vs 3.1 h
Schmitt <i>et al.</i> [14]	Before-after midazolam probe study with saquinavir/ritonavir	18 volunteers; 14 treatment days	Midazolam AUC 12.4-fold, Cmax 4.3-fold higher; half-life 4.7 to 14.9 h
Kirby <i>et al.</i> [15]	Repeated-dose clinical CYP3A probe investigation; RTV/NFV/rifampin	Healthy volunteer studies; 14-day dosing	Oral and IV midazolam AUC increased with RTV/NFV and decreased with rifampin; hepatic and intestinal effects differed
Babany <i>et al.</i> [16]	Biopsy-confirmed chronic amiodarone case series	3; 36-60 months	Fibrosis in 2 and cirrhosis in 1 despite daily maintenance doses near 200 mg

Statins: Biochemical Abnormalities Versus Clinically Severe Hepatotoxicity

The randomized 36-week pravastatin study included 326 participants with compensated chronic liver disease, including nonalcoholic fatty liver disease in 64% and chronic hepatitis C in 23% [5]. The primary liver-test safety event-new ALT $\geq 2 \times$ ULN in those with normal baseline ALT or doubling of baseline ALT in those already elevated-was numerically less frequent with pravastatin than placebo and did not differ significantly. The GREACE post-hoc analysis examined 437 participants with moderately abnormal baseline liver tests; 227 receiving statins demonstrated improvements in liver biochemistry, whereas 210 without statins had further elevations [6]. The study also documented fewer cardiovascular events in the statin-treated subgroup (22/227 Vs 63/210), but nonrandomized subgroup comparisons leave confounding possible.

A substantially larger real-world comparison linked two US claims databases and propensity-matched 232,889 statin initiators with elevated baseline ALT to the same number with normal ALT [7]. The overall incidence rate of severe acute liver injury was approximately 19 per 100,000 person-years, with a pooled hazard ratio of 1.15 (95% CI 0.75-1.75) for elevated versus normal baseline ALT. This estimate is most appropriately interpreted as a comparison of baseline-enzyme strata among statin initiators, not as proof that no statin-associated liver toxicity occurs. Taken together, these studies oppose automatic classification of mild baseline ALT elevation as statin-related metabolic incapacity.

Antituberculosis Regimens: Hepatocellular Toxicity during Extended Treatment

Menzies *et al.* [8] randomized patients requiring latent-tuberculosis treatment to four months of rifampin or nine months of isoniazid. Grade 3-4 hepatitis occurred in 3/418 rifampin-treated participants versus 16/422 isoniazid-

treated participants (risk difference -3.1 percentage points, 95% CI -5 to -1; $p = 0.003$). Treatment completion was 78% versus 60%, respectively. In the subsequent larger multinational randomized trial involving more than 6,800 adults, the difference in grade 3-5 hepatotoxic events within 146 days was -1.2 percentage points (95% CI -1.7 to -0.7), again favoring rifampin [9]. The two trials support drug-specific risk stratification rather than a single risk assumption for all prolonged antituberculosis exposures.

Tweed *et al.* [10] analyzed patients in the REMoxTB trial who had received at least one treatment dose and at least two hepatic-enzyme measurements. Among 1,928 participants, 58 (3.0%) met the study definition of DILI: Peak ALT $\geq 5 \times$ ULN or ALT $\geq 3 \times$ ULN with bilirubin $> 2 \times$ ULN. Median onset was 28 days (IQR 14-56). The study highlights that a course extending over months may produce toxicity relatively early and that extended planned treatment duration and prolonged injury latency are not synonyms. These antituberculosis data primarily measure hepatotoxicity; they do not directly measure CYP clearance in the injured patients.

Enzyme Induction during Long-Term Antiepileptic Treatment

Biochemical induction is prominent in anticonvulsant users. Keefe *et al.* [11] prospectively measured GGT in 58 patients commencing phenytoin: GGT increased from baseline in 52 (90%) after six months, with group mean activity rising from 45.2 ± 9.9 to 135.8 ± 18.1 U/L; elevations persisted at 12 and 24 months. In a separate 110-patient comparison of long-term monotherapy, Aldenhövel reported elevated GGT in 91% of phenytoin users versus 64% of carbamazepine users and elevated ALP in 39% versus 14%, respectively [12]. These enzyme patterns are compatible with induction and do not independently demonstrate hepatocellular necrosis.

A complementary functional experiment examined CYP3A activity directly using orally administered midazolam in six patients receiving carbamazepine or phenytoin and seven controls [13]. Midazolam AUC was only 5.7% of control exposure and C_{max} 7.4%, with half-life 1.3 versus 3.1 hours. This evidence shows why clinical effects of an enzyme-inducing regimen may include inadequate exposure to interacting substrates even when conventional liver-test abnormalities do not establish metabolic failure. Oral midazolam reflects both intestinal and hepatic first-pass effects, so the observed reduction should not be attributed exclusively to hepatic CYP changes.

CYP Inhibition with Antiretroviral Pharmacotherapy

The opposite pharmacokinetic direction was observed under ritonavir-containing treatment. In a repeated-dose clinical experiment of 18 volunteers, 14 days of saquinavir 1,000 mg/ritonavir 100 mg twice daily increased oral midazolam AUC 12.4-fold and C_{max} 4.3-fold; the elimination half-life increased from 4.7 to 14.9 hours [14]. The ratio of hydroxymidazolam-to-parent-drug exposure declined sharply, supporting CYP3A inhibition. A separate clinical study by Kirby *et al.* applied oral and intravenous midazolam probes after approximately 14 days of ritonavir, nelfinavir, or rifampin, finding net CYP3A inhibition with ritonavir, primarily hepatic inhibition with nelfinavir and induction with rifampin [15]. These changes reflect time-dependent inhibition/induction and are pharmacokinetic drug interactions rather than synonymous evidence of hepatocellular injury.

Cumulative Exposure and Histopathological Liver Injury

A histopathological counterexample to benign enzyme induction is provided by Babany *et al.* [16], who reported three patients treated with amiodarone for 36-60 months. Two liver biopsies showed fibrosis and one showed cirrhosis, with hepatic phospholipidosis identified by electron microscopy. Maintenance doses were comparatively low (approximately 200 mg daily in most reported exposure periods), emphasizing the potential importance of cumulative tissue exposure. A three-case series cannot estimate population incidence, establish a dose-response curve, or demonstrate the size of any accompanying CYP-clearance reduction; its evidential role is to document a biologically plausible structural endpoint.

Methodological Appraisal of Included Evidence

The methodological profile differed strongly by outcome. Randomized comparisons provide the most direct evidence for drug-specific relative rates of liver-test elevation and hepatitis, although tolerability run-in, open-label adverse-event ascertainment and subgroup selection can limit transportability. Longitudinal cohorts offer clinically relevant monitoring trajectories but are vulnerable to confounding by preexisting liver conditions, body mass index, co-medication and differential testing. Pharmacokinetic experiments provide direct functional measurements with tightly defined exposure sequences, but small samples and short laboratory induction windows limit generalization to years of treatment. Histological case series establish pathological possibility rather than frequency. Tables 3 and 4 summarize these constraints without reducing noncommensurate study types to one aggregate numerical score.

Table 3: Study-Level Methodological Limitations

Study	Evidence strengths	Important limitation/bias concern
Solomon <i>et al.</i> [3]	Large double-blind randomized comparison; serial ascertainment	Methotrexate-tolerant run-in; population without inflammatory rheumatic disease
Karlsson <i>et al.</i> [4]	Long observation; repeated objective laboratory tests	Single-center observational confounding; frequency of testing varies
Lewis <i>et al.</i> [5]	Blinded randomized comparison; prespecified ALT endpoint	Selected compensated liver-disease population; 36-week horizon
Athyros <i>et al.</i> [6]	Long follow-up and clinically important outcomes	Post-hoc, nonrandomized subgroup comparison; residual confounding
Verma <i>et al.</i> [7]	Large population-based matching; severe clinical outcome	Administrative-code outcome and unmeasured confounding
Menzies <i>et al.</i> [8]	Randomization; adjudicable severe clinical events	Open-label treatment may influence ascertainment
Menzies <i>et al.</i> [9]	Large multinational trial and clinical event monitoring	Open-label regimen and adverse event surveillance variation
Tweed <i>et al.</i> [10]	Serial hepatic measurement within clinical trial	Post-hoc source trial analysis; regimen and host heterogeneity
Keefe <i>et al.</i> [11]	Within-person baseline measurement over months	No randomized untreated comparator; alcohol co-exposure
Aldenhövel [12]	Two commonly prescribed inducer comparators	Retrospective design; historical assay and confounding issues
Backman <i>et al.</i> [13]	Direct CYP3A substrate pharmacokinetic readout	Small n; combined hepatic/intestinal CYP effect
Schmitt <i>et al.</i> [14]	Within-person drug-probe comparisons and metabolite data	18 healthy volunteers; 14-day mechanistic window
Kirby <i>et al.</i> [15]	Oral and IV probe approaches distinguish intestinal/hepatic activity	Healthy-volunteer conditions differ from complex clinical HIV regimens
Babany <i>et al.</i> [16]	Biopsy-confirmed chronic structural lesions	Only three cases; no incidence denominator or unexposed comparator

Table 4: Qualitative Certainty of Evidence

Domain	Certainty judgment	Interpretive basis
Methotrexate and serial aminotransferase changes	Moderate to high	Large randomized enzyme signal with longitudinal cohort corroboration; different event definitions
Comparative antituberculosis hepatotoxicity	Moderate to high	Consistent regimen-specific estimates in large randomized trials; clinically meaningful outcomes
Statin safety with modest baseline ALT elevation	Moderate	Randomized compensated-disease trial and large matched cohort; subgroup confounding remains
Functional CYP3A induction/inhibition	Moderate	Large mechanistic effect sizes and direct probe pharmacokinetic measurement; small short studies
Chronic structural injury from amiodarone	Very low	Histopathological evidence in three selected patients, no frequency estimate
Prediction of CYP function from routine liver-test elevation	Very low	Insufficient same-participant studies jointly quantifying serial ALT and CYP probe clearance

DISCUSSION

Principal Findings and Explanatory Model

The most important conclusion is that biochemical hepatotoxicity and drug metabolic dysfunction follow several distinct pathways. ALT may rise because of membrane injury or cellular stress, whereas GGT or ALP may increase through enzyme induction or cholestatic pathways. CYP induction may accelerate metabolism of other agents and lower exposure; mechanism-based inhibition may lead to higher exposure and prolonged half-life; progressive tissue fibrosis may eventually impair hepatic reserve, yet the magnitude of metabolic change depends on disease severity, transporter function, extraction ratio, inflammation, enzyme isoforms, plasma protein binding and hepatic blood flow. The source studies do not support a universal linear pathway from rising ALT to lower drug clearance.

The methotrexate trials and cohort data demonstrate treatment-related ALT susceptibility [3,4], while statin evidence shows that patients with stable baseline abnormalities are not uniformly at increased risk of severe injury [5-7]. Antituberculosis studies document regimen-specific clinically meaningful hepatic adverse events [8-10]. The phenytoin and carbamazepine data distinguish laboratory induction markers [11,12] from direct acceleration of CYP3A-dependent drug disposition [13]. Ritonavir-containing regimens provide a contrasting pattern of inhibition with sharply increased exposure to a CYP3A probe [14,15]. Histological evidence from amiodarone demonstrates why a minority of prolonged exposures require attention to cumulative damage rather than transient enzyme patterns [16].

Clinical Interpretation of Abnormal Tests

A clinical decision should begin by separating marker, process and outcome. An isolated moderate GGT increase in a phenytoin-treated patient may be consistent with enzyme induction; an ALT increase during methotrexate treatment may signify hepatocyte stress requiring contextual assessment; ALT elevation accompanied by jaundice or worsening INR may indicate more serious injury; and a stable serum ALT does not exclude profound CYP inhibition during ritonavir coadministration. The ALT/ALP ratio pattern, trends after exposure adjustment, concomitant diseases, competing causes and medication chronology are therefore necessary to avoid both inappropriate withdrawal and underrecognition of DILI [2].

Drug metabolic dysfunction is best demonstrated with exposure-response or pharmacokinetic data. AUC, C_{max}, elimination half-life, metabolite-to-parent ratios, or clinically relevant interacting drug concentrations provide much more direct evidence than aminotransferase levels alone. Particularly for drugs with narrow therapeutic indices, prolonged concomitant exposure to CYP inducers or inhibitors has implications for dose selection, therapeutic drug monitoring and time-dependent interaction risk. The intestinal contribution to oral probe changes should always be considered.

Duration, Cumulative Exposure and Latency

Prolonged treatment is a property of prescribing duration, not necessarily of the latency of toxicity. REMoxTB reported a median DILI onset of 28 days during courses designed to last months [10], while amiodarone structural abnormalities were described after three to five years [16]. Enzyme induction and inhibition can also reach clinically important magnitudes over days to weeks [14,15]. Timing of surveillance should therefore be aligned with the expected mechanism: relatively early biochemical screening may identify certain DILI phenotypes, repeated monitoring may track methotrexate-associated elevations and a deliberate interaction review is needed when strong CYP modulators are initiated or stopped.

Strengths and limitations of the Evidence

The synthesis integrates therapeutic hepatotoxicity, direct pharmacokinetic phenotyping and histopathological evidence rather than relying on ALT alone as a surrogate for liver metabolic capacity. Randomized controlled trials provide numerical estimates for important drug comparisons and long-term cohorts contextualize effects in routine prescribing. However, between-study heterogeneity in exposure duration, monitoring schedule, population, baseline liver disease, event thresholds and outcome measurement prevents defensible pooled estimation. A number of classical mechanistic studies are small and histopathological evidence is highly selected. Most critically, the reviewed primary reports seldom measured both serial hepatic biochemistry and CYP functional activity in the same individuals, so correlation or causation between their trajectories remains inadequately established.

Implications for Research and Clinical Pharmacology

Future longitudinal clinical studies should prospectively pair serial ALT, AST, ALP, GGT, total bilirubin, albumin and INR with validated CYP phenotyping or population pharmacokinetic measurements. Cohorts should collect precise dose history, duration, cumulative exposure, polypharmacy, alcohol intake, viral hepatitis status, metabolic dysfunction-associated steatotic liver disease, renal function and relevant pharmacogenetic variation. Prespecified analyses should distinguish adaptive biochemical induction, idiosyncratic injury, cholestatic injury and clinically significant impairment of substrate clearance. Studies of medication withdrawal should quantify both biochemical recovery and de-induction or reversal of CYP inhibition, since these processes can follow different timelines.

CONCLUSION

The hepatic consequences of prolonged pharmacotherapy encompass drug-related liver-test abnormalities, clinically significant hepatotoxicity, sustained induction or inhibition of drug-metabolizing enzymes and occasionally cumulative structural disease. These outcomes differ substantially by medicine and patient context. Low-dose methotrexate increases the probability of serial liver-test abnormalities, antituberculosis therapy carries regimen-specific hepatitis risks and statins are not uniformly associated with severe hepatic injury in people with modest baseline ALT elevation. Phenytoin and carbamazepine can markedly reduce CYP3A substrate exposure, whereas ritonavir-containing therapy can substantially increase it. Routine hepatic enzymes remain important for injury surveillance but cannot substitute for assessment of actual drug-metabolic function. A combined hepatology-clinical pharmacology approach is essential when prescribing, monitoring, or modifying prolonged treatment.

REFERENCES

1. Page, M.J. *et al.* "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews." *BMJ*, vol. 372, 2021, n71.
2. Fontana, R.J. *et al.* "AASLD practice guidance on drug, herbal and dietary supplement-induced liver injury." *Hepatology*, vol. 77, no. 3, 2023, pp. 1036-1065.
3. Solomon, D.H. *et al.* "Adverse effects of low-dose methotrexate: a randomized trial." *Annals of Internal Medicine*, vol. 172, no. 6, 2020, pp. 369-380.
4. Karlsson, S.J. *et al.* "Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance and outcome in clinical practice." *International Journal of Rheumatic Diseases*, vol. 22, no. 7, 2019, pp. 1226-1232.
5. Lewis, J.H. *et al.* "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial." *Hepatology*, vol. 46, no. 5, 2007, pp. 1453-1463.
6. Athyros, V.G. *et al.* "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the GREACE Study: A post-hoc analysis." *The Lancet*, vol. 376, no. 9756, 2010, pp. 1916-1922.
7. Verma, S.K. *et al.* "Statin use and severe acute liver injury among patients with elevated alanine aminotransferase." *Clinical Epidemiology*, vol. 14, 2022, pp. 1535-1545.
8. Menzies, D. *et al.* "Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial." *Annals of Internal Medicine*, vol. 149, no. 10, 2008, pp. 689-697.

9. Menzies, D. *et al.* "Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults." *The New England Journal of Medicine*, vol. 379, no. 5, 2018, pp. 440-453.
10. Tweed, C.D. *et al.* "Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study." *BMC Medicine*, vol. 16, 2018, article 46.
11. Keeffe, E.B. *et al.* "Serum gamma-glutamyl transpeptidase activity in patients receiving chronic phenytoin therapy." *Digestive Diseases and Sciences*, vol. 31, no. 10, 1986, pp. 1056-1061.
12. Aldenhövel, H.G. "The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase." *European Archives of Psychiatry and Neurological Sciences*, vol. 237, no. 5, 1988, pp. 312-316.
13. Backman, J.T. *et al.* "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." *Epilepsia*, vol. 37, no. 3, 1996, pp. 253-257.
14. Schmitt, C. *et al.* "Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe." *Pharmacotherapy*, vol. 29, no. 10, 2009, pp. 1175-1181.
15. Kirby, B.J. *et al.* "Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction and inhibition of cytochrome P450 3A by ritonavir or nelfinavir." *Drug Metabolism and Disposition*, vol. 39, no. 6, 2011, pp. 1070-1078.
16. Babany, G. *et al.* "Chronic liver disease after low daily doses of amiodarone: report of three cases." *Journal of Hepatology*, vol. 3, no. 2, 1986, pp. 228-232.

Abbreviations

ALP, Alkaline Phosphatase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; AUC, Area Under the Concentration-Time Curve; CI, Confidence Interval; C_{max}, Maximum Concentration; CYP, Cytochrome P450; DILI, Drug-Induced Liver Injury; GGT, Gamma-Glutamyltransferase; HR, Hazard Ratio; INR, International Normalized Ratio; RCT, Randomized Controlled Trial; ULN, Upper Limit Of Normal